WHAT IS CLAIMED IS:

1. A composition comprising a *Sanguisorbae officinalis* plant extract and at least one additional plant extract selected from the group consisting of an *Ailanthus altissima* plant extract, a *Galla rhois gallnut* plant extract, a *Glycyrrhiza Glabra* plant extract, a *Rheum palmatum* plant extract and a *Scutellaria baicalensis* plant extract.

2. A method of treating and/or preventing atopic dermatitis (AD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition comprising *a Sanguisorbae officinalis* plant extract and *an Ailanthus altissima* plant extract, thereby treating and/or preventing the infection in the subject.

3. Use of a composition comprising *a Sanguisorbae officinalis* plant extract and *an Ailanthus altissima* plant extract for the treatment and/or prevention of atopic dermatitis (AD) in a subject in need thereof.

4. A composition comprising a plant extract, wherein said plant is selected from the group consisting of *Galla rhois gallnut*, *Peucedanum praeruptorum* and *Cimicifuga raceomosa*.

5. The composition of claim 1, wherein said composition comprises said *Sanguisorbae officinalis* plant extract, said *Ailanthus altissima* plant extract and said *Glycyrrhiza Glabra* plant extract.

6. The composition of claim 1, wherein said composition comprises said *Sanguisorbae officinalis* plant extract, said *Ailanthus altissima* plant extract and said *Galla rhois gallnut* plant extract.

7. The composition of claim 1, wherein said composition comprises said *Sanguisorbae officinalis* plant extract and said *Ailanthus altissima* plant extract.

8. The composition of claim 1, wherein said composition comprises said *Sanguisorbae officinalis* plant extract and said *Galla rhois gallnut* plant extract.

9. The composition of claim 1, wherein said composition comprises said *Sanguisorbae officinalis* plant extract and said *Glycyrrhiza Glabra* plant extract.

10. The composition of claim 1, wherein said composition comprises said *Sanguisorbae officinalis* plant extract and said *Rheum palmatum* plant extract.

11. The composition of claim 1, wherein said composition comprises said *Sanguisorbae officinalis* plant extract and said *Scutellaria baicalensis* plant extract.

12. A composition comprising an *Ailanthus altissima* plant extract and at least one additional plant extract selected from the group consisting of a *Galla rhois gallnut* plant extract, a *Glycyrrhiza Glabra* plant extract, a *Rheum palmatum* plant extract and a *Scutellaria baicalensis* plant extract.

13. A composition comprising Ailanthone at a concentration of at least about 0.01 % and a cosmetically or a pharmaceutically acceptable carrier.

14. The composition of claim 13, wherein said composition further comprises *Sanguisorbae officinalis* plant extract.

15. The composition of claims 13 or 14, further comprising a plant extract selected from the group consisting of a *Galla rhois gallnut* plant extract, a *Glycyrrhiza Glabra* plant extract a *Rheum Palmatum* Root Extract, a *Cnidium Monnieri* Fruit Extract and a *Scutellaria Baicalensis* Root Extract.

16. The composition of claim 15, further comprising Dipotassium Glycyrrhizate.

17. The composition of any one of claims 1 or 4-16 formulated for topical, ocular, oral or pulmonary administration.

18. The composition of claim 13, wherein said concentration of said Ailanthone is about 0.01-1 %.

19. The composition of claim 13, wherein said concentration of said Ailanthone is about 0.01-5 %.

20. The composition of claim 1, wherein said *Sanguisorbae officinalis* plant extract and said at least one additional plant extract are formulated in a co-formulation.

21. The composition of claim 1, wherein said *Sanguisorbae officinalis* plant extract and said at least one additional plant extract are formulated in separate formulations.

22. The composition of claim 1 or 12, wherein a concentration of each of said plant extracts in said composition is in the range of 0.01-10 %.

23. The composition of claim 1 or 12, wherein a concentration of each of said plant extracts in said composition is in the range of 0.5-2 %.

24. The composition of claim 1 or 12, wherein a concentration of each of said plant extracts in said composition is 1 %.

25. The composition of claim 4, wherein a concentration of said plant extract in said composition is in the range of 0.01-10 %.

26. The composition of claim 4, wherein a concentration of said plant extract in said composition is in the range of 0.5-2 %.

27. The composition of claim 4, wherein a concentration of said plant extract in said composition is 1 %.

28. The composition of any of claims 1, 5, 6, 7 or 12, method of claim 2, or use of claim 3, wherein said *Ailanthus altissima* plant extract comprises at least about 0.01 % Ailanthone.

29. The composition of any of claims 1, 5, 6, 7 or 12, method of claim 2, or use of claim 3, wherein said *Ailanthus altissima* plant extract consists of *Ailanthi radicis* plant extract.

30. The composition, method or use of claim 29, wherein said *Ailanthi radicis* plant extract is a polar extract.

31. The composition, method or use of claim 30, wherein said polar extract is extracted using a polar solvent selected from the group consisting of a butyl alcohol and an ethyl alcohol.

32. The composition, method or use of claim 29, wherein said *Ailanthi radicis* plant extract is further purified using a high-performance liquid chromatography (HPLC).

33. The composition of claim 1, 4 or 12, wherein said plant extract comprises an aqueous plant extract.

34. The composition of claim 33, wherein said aqueous plant extract is further purified using a resin chromatography.

35. The composition of claim 34, wherein said resin chromatography comprises a macroporous resin.

36. The composition of any one of claims 1 or 4-27, wherein said composition does not comprise a beta-defensin.

37. The composition of any one of claims 1 or 4-27, wherein said composition is a pharmaceutical composition and comprises a pharmaceutically acceptable carrier or diluent.

38. The composition of any one of claims 1 or 4-27, wherein said composition is a cosmetic composition and comprises a cosmetically acceptable carrier or diluent.

39. The composition of claim 38, wherein said cosmetically acceptable carrier or diluent is formulated in a form selected from the group consisting of a cream, a gel, a spray, a lotion, an ointment, an oil, a wash, a shampoo, a soap and a spray.

40. A method of treating and/or preventing an infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition of any one of claims 1 or 4-27, thereby treating and/or preventing the infection in the subject.

41. Use of the composition of any one of claims 1 or 4-27 for the treatment and/or prevention of an infection in a subject in need thereof.

42. The method of claim 40 or use of claim 41, wherein said infection is secondary to chronic inflammation.

43. The method of claim 40 or use of claim 41, wherein said infection is associated with a disease selected from the group consisting of an atopic disease, a contact dermatitis, a nummular dermatitis, a radiation dermatitis, a burn, a non-atopic eczema, a pressure sore, an eye inflammatory disease, a respiratory inflammatory diseases, an asthma, a gastrointestinal disease and an oral infectious disease.

44. The method of claims 2 or 40, or use of claims 3 or 41, wherein said subject is a human being.

45. The method of claims 2 or 40, wherein said therapeutically effective amount is for downregulating secretion of a Th2 type cytokine in a cell of said subject.

46. The method of claim 45, wherein said Th2 type cytokine is selected from the group consisting of IL-4, IL-5, IL-6, IL-10 and IL-13.

47. The method of claims 2 or 40, wherein said therapeutically effective amount is for upregulating expression of a human beta-defensin in a cell of said subject.

48. The method of claims 2 or 40, wherein said therapeutically effective amount comprises an anti-microbial activity.

49. A delivery system comprising an applicator and the composition of any one of claims 1 or 4-27 contained within.

50. The delivery system of claim 49, wherein said applicator is in a form selected from the group consisting of an adhesive bandage, a non-adhesive bandage, a wipe, a gauze and a pad.

51. A unit dosage form comprising *Sanguisorbae officinalis* plant extract at a concentration of about 0.5-2 % weight/weight.

52. The unit dosage form of claim 51, further comprising *Ailanthus altissima* plant extract at a concentration of about 0.5-2 % weight/weight.

53. The unit dosage form of claim 51, further comprising *Glycyrrhiza Glabra* plant extract at a concentration of about 0.5-2 % weight/weight.

54. The unit dosage form of claim 51, further comprising *Galla rhois gallnut* plant extract at a concentration of about 0.5-2 % weight/weight.

55. The unit dosage form of claim 51, further comprising *Rheum palmatum* plant extract at a concentration of about 0.5-2 % weight/weight.

56. The unit dosage form of claim 51, further comprising *Scutellaria baicalensis* plant extract at a concentration of about 0.5-2 % weight/weight.

57. A unit dosage form comprising *Ailanthus altissima* plant extract at a concentration of about 0.5-2 % weight/weight.

58. A unit dosage form comprising *Glycyrrhiza Glabra* plant extract at a concentration of about 0.5-2 % weight/weight.

59. A unit dosage form comprising *Galla rhois gallnut* plant extract at a concentration of about 0.5-2 % weight/weight.

60. A unit dosage form comprising *Sanguisorbae officinalis* plant extract at a concentration of about 0.5-2 % weight/weight, *Ailanthus altissima* plant extract at a concentration of about 0.5-2 % weight/weight and *Glycyrrhiza Glabra* plant extract at a concentration of about 0.5-2 % weight/weight.

61. A unit dosage form comprising *Sanguisorbae officinalis* plant extract at a concentration of about 0.5-2 % weight/weight, *Ailanthus altissima* plant extract at a concentration of about 0.5-2 % weight/weight and *Galla rhois gallnut* plant extract at a concentration of about 0.5-2 % weight/weight.

62. The unit dosage form of any of claims 51-61, wherein said concentration of said plant extract is 1 % weight/weight.

63. A unit dosage form selected from the group consisting of a topical, an oral, a pulmonary or an ocular unit dosage form comprising Ailanthone at a concentration of at least about 0.01 % weight/weight.

64. The unit dosage form of claim 63, wherein said concentration of said Ailanthone is about 0.01-1 % weight/weight.

65. The unit dosage form of any one of claims 51-64, is in a form selected from the group consisting of an adhesive bandage, a non-adhesive bandage, a wipe, a gauze and a pad.

66. The composition of any one of claims 1 or 4-27, delivery system of claim 49 or unit dosage form of any one of claims 51-64, further comprising a factor selected from the group consisting of an extracellular matrix component, a growth factor, a hormone, an angiogenic factor, a coagulation factor, a cytokine inhibitor, a chemokine inhibitor, an enzyme, a neurotransmitter, a vitamin, a carbohydrate, an ion, an iron chelator, a fatty acid, an anti-microbial agent, an antibiotic, a steroid and an amino acid.

67. The method of any one of claims 2 or 40, wherein said administering is effected chronically.

68. The method of any one of claims 2 or 40, wherein said administering is effected at least once a day.

69. The method of any one of claims 2 or 40, wherein said administering is effected for at least 21 days.

70. A method of preparing a composition for treating and/or preventing an infection, the method comprising:

(a) subjecting a plant to x 1-10 volumes of water to produce an extract of said plant; and

(b) reducing the amount of organic salts and/or heavy metals and/or starch in said plant extract using a macroporous resin which results in an elevated content of an active ingredient which is present in said plant extract.

71. The method of claim 70, wherein said plant is selected from the group consisting of *Ailanthus altissima*, *Galla rhois gallnut*, *Peucedanum praeruptorum*, *Glycyrrhiza glabra*, *Cimicifuga raceomosa*, *Silybum marianum*, *Sanguisorbae officinalis*, *Rheum palmatum* and *Scutellaria baicalensis*.

72. The method of claim 71, wherein said *Ailanthus altissima* consists of *Ailanthi radicis*.

73. The method of claim 70, wherein said active ingredient is selected from the group consisting of Ailanthone, Mersosin, Toosendanin, General Ginsenoide, Galic acid, Liquiritin, Praeruptorin A, Tannic acid and Silybin.

74. The method of claim 71, wherein when said plant comprises *Ailanthi altissima*, said active ingredient comprises Ailanthone.

75. A method of identifying an agent having inflammatory modulator properties, the method comprising:

(a) contacting the agent with a cell; and

(b) assaying secretion of a human beta-defensin from said cell, wherein an upregulation in said beta-defensin secretion following said contacting is indicative that the agent has an inflammatory modulator properties.

76. The method of claim 75, wherein said agent comprises a plant extract or active ingredient thereof.

77. The method of claim 75, wherein said cell comprises a keratinocyte cell.

78. A cosmetic carrier comprising a *Rheum Palmatum* Root Extract, a *Cnidium Monnieri* Fruit Extract, a *Scutellaria Baicalensis* Root Extract and Dipotassium Glycyrrhizate.

79. A cosmetic composition comprising a *Sanguisorbae officinalis* plant extract, an *Ailanthus altissima* plant extract, a *Rheum Palmatum* Root Extract, a *Cnidium Monnieri* Fruit Extract, a *Scutellaria Baicalensis* Root Extract and Dipotassium Glycyrrhizate.

80. The cosmetic composition of claim 79, further comprising a moisturizer and an emollient.

WHAT IS CLAIMED IS:

1. A composition comprising a therapeutically effective amount of *Sanguisorbae officinalis* plant extract and *an Ailanthus altissima* plant extract for treating and/or preventing infection in a subject in need thereof.

2. A composition according to claim 1, wherein the infection is secondary to chronic inflammation or to atopic dermatitis (AD).

3. The composition of claim 2, wherein said infection is associated with a disease selected from the group consisting of an atopic disease, a contact dermatitis, a nummular dermatitis, a radiation dermatitis, a burn, a non-atopic eczema, a pressure sore, an eye inflammatory disease, a respiratory inflammatory diseases, an asthma, a gastrointestinal disease and an oral infectious disease.

4. The composition of any one of claims 1-3, wherein said therapeutically effective amount is for downregulating secretion of a Th2 type cytokine selected from the group consisting of IL-4, IL-5, IL-6, IL-10 and IL-13 in a cell of said subject.

5. The composition of any one of claims 1-4, wherein said therapeutically effective amount is for upregulating expression of a human beta-defensin in a cell of said subject.

6. The composition of any one of claims 1-5, wherein the composition further comprises one or more of a *Galla rhois gallnut* plant extract, a *Glycyrrhiza Glabra* plant extract, a *Rheum palmatum* plant extract, a *Scutellaria baicalensis* plant extract, *Peucedanum praeruptorum* plant extract, *Cimicifuga raceomosa* plant extract, *Silybum marianum* plant extract and *Dipotassium Glycyrrhizate*.

7. A composition comprising a therapeutically effective amount of *Sanguisorbae officinalis* plant extract and Ailanthone at a concentration of at least about 0.01% w/w for treating and/or preventing infection in a subject in need thereof.

8. A composition according to claim 7, wherein the infection is secondary to chronic inflammation or to atopic dermatitis (AD).

9. The composition of claim 7, wherein said infection is associated with a disease selected from the group consisting of an atopic disease, a contact dermatitis, a nummular dermatitis, a radiation dermatitis, a burn, a non-atopic eczema, a pressure sore, an eye inflammatory disease, a respiratory inflammatory diseases, an asthma, a gastrointestinal disease and an oral infectious disease.

10. The composition of claim 7, wherein said composition further comprises one or more plant extract selected from the group consisting of a *Galla rhois gallnut* plant extract, a *Glycyrrhiza Glabra* plant extract, a *Rheum Palmatum* Root Extract, a *Cnidium Monnieri* Fruit Extract and a *Scutellaria Baicalensis* Root Extract.

11. The composition of claim 1, wherein said *Sanguisorbae officinalis* plant extract and *Ailanthus altissima* plant extract comprises an aqueous plant extract further purified using a resin chromatography comprising a macroporous resin.

12. A unit dosage form comprising *Sanguisorbae officinalis* plant extract at a concentration of about 0.5-2 % weight/weight; *Ailanthus altissima* plant extract at a concentration of about 0.5-2 % weight/weight or Ailanthone at a concentration of at least 0.01% w/w; and *Scutellaria Baicalensis* Root Extract or *Rheum Palmatum* Root Extract or a combination thereof at a concentration of about 0.5-2 % weight/weight.